2003
DOI: 10.1086/367990
|View full text |Cite
|
Sign up to set email alerts
|

Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia

Abstract: E5564 is a second-generation synthetic analogue of the lipid A component of endotoxin (lipopolysaccharide [LPS]). The ability of E5564 to block the toxic activity of LPS was assessed in a double-blind, placebo-controlled study. A bolus infusion of endotoxin (4 ng/kg) was administered to healthy subjects to induce a mild transient syndrome similar to clinical sepsis. Single E5564 doses of 50-250 microg ameliorated or blocked all of the effects of LPS in a dose-dependent manner. All E5564 dose groups had statist… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
98
0
2

Year Published

2005
2005
2016
2016

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 146 publications
(102 citation statements)
references
References 23 publications
2
98
0
2
Order By: Relevance
“…At present, several synthetic lipid A analogs have been developed as TLR4 antagonists, and their potential application in the treatment of severe sepsis is under vigorous preclinical and clinical trials. [58][59][60] Whether these compounds also exert effective control over DN definitely deserves further studies in animal models of DN.…”
Section: Discussionmentioning
confidence: 99%
“…At present, several synthetic lipid A analogs have been developed as TLR4 antagonists, and their potential application in the treatment of severe sepsis is under vigorous preclinical and clinical trials. [58][59][60] Whether these compounds also exert effective control over DN definitely deserves further studies in animal models of DN.…”
Section: Discussionmentioning
confidence: 99%
“…1) and corresponds to the dose in humans that produces a mild transient syndrome similar to clinical sepsis (61,62). In PBMC from 8 donors, 1 g/ml Hsp10 mediated an average 23.7% reduction, and 10 g/ml mediated an average 23.3% reduction in LPS-induced TNF-␣ secretion (Fig.…”
Section: Hsp10 Inhibits Lps-induced Inflammatory Mediator Productionmentioning
confidence: 99%
“…The lipid A moiety of LPS is usually required for bacterial growth (3,4) and is a potent activator of the mammalian innate immune system via the TLR4/MD-2 complex (5,6). Over-production of cytokines due to excessive stimulation of TLR4/MD-2 may occur during severe Gram-negative infections and may contribute to the life-threatening complications of septic shock (7,8).The Kdo 2 -lipid A substructure of Escherichia coli LPS is synthesized by a conserved system of nine constitutive enzymes (Fig. 1A) (3).…”
mentioning
confidence: 99%